AbCellera Biologics Inc. ABCL Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$143.96M+1.7% | -$146.41M+14.7% | -$171.68M-3.6% | -$165.67M+1.3% | -$167.87M-3.1% | ||
| $19.9M+8.2% | $18.39M+20.1% | $15.31M+3.4% | $14.81M+8.0% | $13.71M+10.1% | ||
| $53.02M-5.0% | $55.79M-4.0% | $58.11M-5.3% | $61.38M-5.5% | $64.96M-3.9% | ||
| -$2.54M-173% | $3.46M-20.2% | $4.33M+27.0% | $3.41M-71.8% | $12.1M+13.8% | ||
| -$8.09M+52.8% | -$17.15M+9.9% | -$19.02M+8.9% | -$20.88M-23.7% | -$16.88M-183% | ||
| $3.17M-4.9% | $3.33M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$30.41M-1.9% | -$29.84M-573% | -$4.43M-188% | $5.02M-7.5% | $5.43M-18.4% | ||
| —— | —— | —— | —— | —— | ||
| $7.19M+8.2% | $6.65M+7.4% | $6.19M+11.0% | $5.58M+1.3% | $5.5M-10.5% | ||
| $41.39M-25.6% | $55.62M+51.1% | $36.82M-30.8% | $53.21M-7.7% | $57.68M-23.2% | ||
| —— | $30.11M+33.3% | $22.58M+50.0% | $15.06M+100% | $7.53M— | ||
| -$153.26M-16.7% | -$131.3M-25.6% | -$104.55M-29.3% | -$80.84M-3.1% | -$78.4M+27.8% | ||
| $35.97M-15.9% | $42.77M-11.9% | $48.56M-16.5% | $58.15M-10.4% | $64.89M-17.2% | ||
| —— | -$33.27M-33.3% | -$24.95M-50.0% | -$16.63M-100% | -$8.32M— | ||
| $54.73M-37.6% | $87.75M+81.6% | $48.32M+211% | $15.53M-84.4% | $99.43M-18.1% | ||
| —— | —— | —— | —— | $15.91M+24.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$43.48M+22.2% | -$55.88M-257% | $35.69M+55.2% | ||
| $3.7M-0.1% | $3.7M— | —— | —— | —— | ||
| $19.9M+8.2% | $18.39M+20.1% | $15.31M+3.4% | $14.81M+8.0% | $13.71M+10.1% | ||
| —— | $30.11M+33.3% | $22.58M+50.0% | $15.06M+100% | $7.53M— | ||
| —— | -$4.53M-135% | $12.79M-57.5% | $30.1M-36.5% | $47.41M-26.7% | ||
| $4.77M+31.2% | $3.64M+887% | -$462K+96.3% | -$12.53M+41.6% | -$21.47M+36.8% | ||
| —— | —— | —— | —— | —— | ||
| -$8.09M+52.8% | -$17.15M+9.9% | -$19.02M+8.9% | -$20.88M-23.7% | -$16.88M-183% | ||
| $7.19M+8.2% | $6.65M+7.4% | $6.19M+11.0% | $5.58M+1.3% | $5.5M-10.5% | ||
| $3.17M-4.9% | $3.33M— | —— | —— | —— | ||
| —— | -$33.27M-33.3% | -$24.95M-50.0% | -$16.63M-100% | -$8.32M— | ||
| $9.71M-43.2% | $17.09M— | —— | —— | —— | ||
| $21.69M+1.6% | $21.34M+53.3% | $13.92M-37.9% | $22.41M-24.2% | $29.56M-17.2% | ||
| —— | $29.73M+15.8% | $25.67M+18.8% | $21.61M+23.1% | $17.56M+30.1% | ||
| —— | —— | —— | —— | —— | ||
| -$189.23M-8.7% | -$174.07M-13.7% | -$153.11M-10.2% | -$138.99M+3.0% | -$143.29M+23.4% | ||
| -$189.23M-8.7% | -$174.07M-13.7% | -$153.11M-10.2% | -$138.99M+3.0% | -$143.29M+23.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does AbCellera Biologics Inc. generate?
- AbCellera Biologics Inc. (ABCL) generated -$153.3M in operating cash flow over the trailing twelve months.
- What is AbCellera Biologics Inc.'s free cash flow?
- After $36.0M of capital expenditures, AbCellera Biologics Inc.'s free cash flow was -$189.2M over the trailing twelve months, down 32.1% year over year.
- Where does AbCellera Biologics Inc.'s cash flow data come from?
- Every line is extracted from AbCellera Biologics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
